Myocardial F-18 fluorodeoxyglucose imaging by SPECT

Area of Science:

• Nuclear cardiology
• Medical imaging
• Cardiovascular disease

Background:

• F-18 fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) accurately detects viable myocardium in coronary artery disease (CAD).
• Widespread clinical use of FDG PET is limited by the limited availability of PET centers.
• Previous studies demonstrated the feasibility of imaging 511 keV with planar scintigraphy and myocardial FDG uptake using SPECT.

Purpose of the Study:

• To evaluate the feasibility and value of FDG SPECT in predicting recovery of contractile function before revascularization in patients undergoing bypass surgery.
• To assess the potential of FDG SPECT as an alternative to FDG PET for detecting viable myocardium in CAD patients.

Main Methods:

• Myocardial FDG uptake was studied in normal volunteers and CAD patients using SPECT.
• The study investigated the value of FDG SPECT to predict recovery of contractile function before revascularization in patients undergoing bypass surgery.

Main Results:

• FDG SPECT appears feasible for assessing myocardial viability.
• FDG SPECT can predict the reversibility of wall motion abnormalities in CAD patients.
• The findings suggest FDG SPECT may be a viable alternative to FDG PET for detecting viable myocardium.

Conclusions:

• FDG SPECT is a feasible technique for detecting viable myocardium in patients with coronary artery disease.
• FDG SPECT shows potential in predicting the recovery of contractile function before revascularization.
• Further comparative studies are needed to establish the role of FDG SPECT against other viability detection techniques.